{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:09:21Z","timestamp":1789207761744,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jgo.2026.104122","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:36:31Z","timestamp":1789144591000},"page":"104122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-surgical therapies for localized non-melanoma skin cancer in older adults: A review"],"prefix":"10.1016","volume":"18","author":[{"given":"Selene M.","family":"Kizy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke T.","family":"Baylis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Nellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzie","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Caudill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jgo.2026.104122_bb0005","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09940-3","article-title":"Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25years","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Cancer."},{"issue":"9","key":"10.1016\/j.jgo.2026.104122_bb0010","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00403-013-1357-2","article-title":"Age distribution of patients with advanced non-melanoma skin cancer in the United States","volume":"305","author":"Dacosta Byfield","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jgo.2026.104122_bb0015","series-title":"Current population reports","article-title":"Demographic turning points for the United States: Population projections for 2020 to 2060","volume":"P25\u20131144","author":"Vespa","year":"2020"},{"issue":"4","key":"10.1016\/j.jgo.2026.104122_bb0020","article-title":"Updates on the management of non-melanoma skin cancer (NMSC)","volume":"5","author":"Fahradyan","year":"2017","journal-title":"Healthcare (Basel)."},{"issue":"7","key":"10.1016\/j.jgo.2026.104122_bb0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/jamadermatol.2022.1733","article-title":"Nonmelanoma skin cancer in patients older than age 85 years presenting for Mohs surgery: a prospective, multicenter cohort study","volume":"158","author":"Maisel-Campbell","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jgo.2026.104122_bb0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2024.12708","article-title":"Perioperative Management of Patients Taking Direct Oral Anticoagulants: a review","volume":"332","author":"Douketis","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jgo.2026.104122_bb0035","series-title":"National Health Statistics Reports; no 203","article-title":"Diagnosed dementia in adults age 65 and older: United States, 2022","author":"Kramarow","year":"2024"},{"key":"10.1016\/j.jgo.2026.104122_bb0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12939-025-02429-y","article-title":"Barriers to health, social and long-term care access among older adults: a systematic review of reviews","volume":"24","author":"Caba\u00f1ero-Garcia","year":"2025","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.jgo.2026.104122_bb0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.addr.2019.11.002","article-title":"Topical treatments for skin cancer","volume":"153","author":"Cullen","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.jgo.2026.104122_bb0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/DSS.0000000000004044","article-title":"Topical treatment of cutaneous squamous cell carcinoma in situ and the impact of clinical risk factors and positive histologic margins at the time of diagnosis","volume":"50","author":"Calley","year":"2024","journal-title":"Dermatol Surg"},{"issue":"15","key":"10.1016\/j.jgo.2026.104122_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153927","article-title":"Topical treatments for basal cell carcinoma and actinic keratosis in the United States","volume":"15","author":"Tan","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/09546634.2010.507704","article-title":"Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders","volume":"23","author":"Ceilley","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jgo.2026.104122_bb0065","first-page":"433","article-title":"5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction","volume":"33","author":"Gross","year":"2007","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.08.045","article-title":"Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: a retrospective cohort analysis","volume":"87","author":"Neale","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.jgo.2026.104122_bb0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0080","first-page":"22","article-title":"Considerations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients","volume":"1","author":"Werschler","year":"2008","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"10.1016\/j.jgo.2026.104122_bb0085","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/bjd.13066","article-title":"Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma","volume":"171","author":"Arits","year":"2014","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.jgo.2026.104122_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"Br J Dermatol"},{"issue":"15","key":"10.1016\/j.jgo.2026.104122_bb0095","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/djg016","article-title":"Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod","volume":"95","author":"Sch\u00f6n","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.jgo.2026.104122_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310835","article-title":"Imiquimod as local immunotherapy in the management of premalignant cutaneous conditions and skin cancer","volume":"24","author":"Garcia-Mouronte","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jgo.2026.104122_bb0105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/1203475420931770","article-title":"Topical Imiquimod as a treatment option for nodular basal cell carcinoma: a systematic review","volume":"24","author":"Huang","year":"2020","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"10.1016\/j.jgo.2026.104122_bb0110","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/archdermatol.2009.291","article-title":"Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review","volume":"145","author":"Love","year":"2009","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jgo.2026.104122_bb0115","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jid.2016.10.019","article-title":"Surgery versus 5% Imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial","volume":"137","author":"Williams","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jgo.2026.104122_bb0120","doi-asserted-by":"crossref","DOI":"10.1007\/s00403-024-03032-x","article-title":"Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization","volume":"316","author":"DeTemple","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"48","key":"10.1016\/j.jgo.2026.104122_bb0125","doi-asserted-by":"crossref","first-page":"18099","DOI":"10.1074\/jbc.RA119.010732","article-title":"Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of \u03b2-tubulin explains KXO1\u2019s low clinical toxicity","volume":"294","author":"Niu","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jgo.2026.104122_bb0130","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/CCID.S374122","article-title":"Tirbanibulin for actinic keratosis: insights into the mechanism of action","volume":"15","author":"Schlesinger","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/ced\/llad334","article-title":"Tirbanibulin ointment to manage recurrence of superficial basal cell carcinoma of the face: case report","volume":"49","author":"Martora","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jgo.2026.104122_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdcr.2022.07.035","article-title":"Rapid resolution of recalcitrant basal cell carcinoma of the ear with topical tirbanibulin","volume":"28","author":"Moore","year":"2022","journal-title":"JAAD Case Rep."},{"issue":"9","key":"10.1016\/j.jgo.2026.104122_bb0145","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/ced\/llad171","article-title":"Successful treatment of field cancerization on the dorsum of the hands with 1% tirbanibulin ointment","volume":"48","author":"Abril-P\u00e9rez","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jgo.2026.104122_bb0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdcr.2021.06.013","article-title":"Topical tirbanibulin eradication of periungual squamous cell carcinoma","volume":"14","author":"Moore","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jgo.2026.104122_bb0155","first-page":"938","article-title":"Retinoids as anti-cancer agents and their mechanisms of action","volume":"12","author":"Jin","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"13","key":"10.1016\/j.jgo.2026.104122_bb0160","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/0008-5472.CAN-03-1927","article-title":"Topical tazarotene chemoprevention reduces basal cell carcinoma number and size in Ptch1+\/\u2212 mice exposed to ultraviolet or ionizing radiation","volume":"64","author":"So","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jgo.2026.104122_bb0165","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1158\/1535-7163.MCT-07-2043","article-title":"Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis","volume":"7","author":"So","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.jgo.2026.104122_bb0170","first-page":"1435","article-title":"Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion","volume":"58","author":"Tennenbaum","year":"1998","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"10.1016\/j.jgo.2026.104122_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0304-3835(95)03868-W","article-title":"High dietary retinoic acid inhibits tumor promotion and malignant conversion in a two-stage skin carcinogenesis protocol using 7,12-dimethylbenz[a]anthracene as the initiator and mezerein as the tumor promoter in female SENCAR mice","volume":"95","author":"Chen","year":"1995","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.jgo.2026.104122_bb0180","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1067\/S0190-9622(03)01587-1","article-title":"Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study","volume":"49","author":"Nijsten","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jgo.2026.104122_bb0185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ad.2018.01.007","article-title":"Update on the Treatment of molluscum Contagiosum in children. Actualizaci\u00f3n sobre el tratamiento de moluscos contagiosos en los ni\u00f1os","volume":"109","author":"Gerlero","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)."},{"key":"10.1016\/j.jgo.2026.104122_bb0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CCID.S127040","article-title":"Superficial basal cell carcinoma treated with 70% trichloroacetic acid applied topically: a case study","volume":"10","author":"Chiriac","year":"2017","journal-title":"Clin Cosmet Investig Dermatol."},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0195","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/09546634.2019.1589642","article-title":"A patient with squamous cell carcinoma in-situ successfully treated with intralesional 5-fluorouracil and topical trichloroacetic acid","volume":"31","author":"Vazquez","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jgo.2026.104122_bb0200","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jaad.2020.12.049","article-title":"Intralesional 5-fluorouracil for the treatment of squamous cell carcinomas","volume":"84","author":"Maxfield","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.36849\/JDD.5518","article-title":"Intralesional 5-fluorouracil for treatment of non-melanoma skin Cancer: a systematic review","volume":"20","author":"Maghfour","year":"2021","journal-title":"Journal of drugs in dermatology : JDD"},{"issue":"3","key":"10.1016\/j.jgo.2026.104122_bb0210","article-title":"Intralesional 5-fluorouracil in the treatment of squamous cell carcinoma in an elderly patient","volume":"16","author":"McDonald","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jgo.2026.104122_bb0215","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdcr.2022.04.016","article-title":"Successful treatment of squamous cell carcinoma with intralesional methotrexate","volume":"24","author":"Vega-Gonz\u00e1lez","year":"2022","journal-title":"JAAD case reports"},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15233","article-title":"Effectiveness of neoadjuvant intralesional methotrexate in cutaneous squamous cell carcinoma: a prospective cohorts study","volume":"35","author":"Berg\u00f3n-Send\u00edn","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jgo.2026.104122_bb0225","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/archderm.1960.01580050104016","article-title":"Effects of methotrexate on basal-cell carcinomas","volume":"82","author":"Van Scott","year":"1960","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.jgo.2026.104122_bb0230","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/09546634.2018.1451817","article-title":"Treatment of basal cell carcinoma: is intralesional methotrexate an option?","volume":"29","author":"Balighi","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jgo.2026.104122_bb0235","series-title":"StatPearls [Internet]","article-title":"Cryotherapy in Dermatology","author":"Prohaska","year":"2025"},{"issue":"2 Pt 2","key":"10.1016\/j.jgo.2026.104122_bb0240","first-page":"297","article-title":"Cryosurgery for skin cancer: 30-year experience and cure rates","volume":"30","author":"Kuflik","year":"2004","journal-title":"Dermatologic surgery\u202f: official publication for American Society for Dermatologic Surgery [et al]"},{"issue":"9","key":"10.1016\/j.jgo.2026.104122_bb0245","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-4632.2011.04969.x","article-title":"Prospective trial of curettage and cryosurgery in the management of non-facial, superficial, and minimally invasive basal and squamous cell carcinoma","volume":"50","author":"Peikert","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jgo.2026.104122_bb0250","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/IMCRJ.S375871","article-title":"Cryotherapy as an effective therapeutic option in patients with nodular basal cell carcinoma - case report","volume":"15","author":"Sutedja","year":"2022","journal-title":"International medical case reports journal"},{"key":"10.1016\/j.jgo.2026.104122_bb0255","unstructured":"Curettage & Electrodesiccation | Skin Cancer Treatment."},{"issue":"7","key":"10.1016\/j.jgo.2026.104122_bb0260","first-page":"773","article-title":"Controversies in skin surgery: electrodessication and curettage versus excision for low-risk, small, well-differentiated squamous cell carcinomas","volume":"9","author":"Reschly","year":"2010","journal-title":"Journal of drugs in dermatology\u202f: JDD"},{"issue":"10","key":"10.1016\/j.jgo.2026.104122_bb0265","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/jdv.18209","article-title":"Curettage vs. cryosurgery for superficial basal cell carcinoma: a prospective, randomised and controlled trial","volume":"36","author":"Backman","year":"2022","journal-title":"Journal of the European Academy of Dermatology and Venereology\u202f: JEADV"},{"issue":"6","key":"10.1016\/j.jgo.2026.104122_bb0270","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.jaad.2006.01.041","article-title":"Treatment of basal cell carcinoma with curettage alone","volume":"54","author":"Barlow","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jgo.2026.104122_bb0275","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00403-021-02248-5","article-title":"Wound care quality of life in aging patients undergoing electrodessication and curettage on the back","volume":"314","author":"Pretzlaff","year":"2022","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"10.1016\/j.jgo.2026.104122_bb0280","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/DSS.0000000000003855","article-title":"Electrodesiccation and curettage for squamous cell carcinoma in situ: the effect of anatomic location on local recurrence","volume":"49","author":"Veverka","year":"2023","journal-title":"Dermatologic surgery\u202f: official publication for American Society for Dermatologic Surgery [et al.]"},{"key":"10.1016\/j.jgo.2026.104122_bb0285","first-page":"145","article-title":"Current evidence and applications of photodynamic therapy in dermatology","volume":"7","author":"Wan","year":"2014","journal-title":"Clinical, cosmetic and investigational dermatology"},{"issue":"5","key":"10.1016\/j.jgo.2026.104122_bb0290","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaad.2019.10.079","article-title":"Photodynamic therapy for cutaneous squamous cell carcinoma in situ: impact of anatomic location, tumor diameter, and incubation time on effectiveness","volume":"82","author":"Kibbi","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jgo.2026.104122_bb0295","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1468-3083.2010.03877.x","article-title":"Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response","volume":"25","author":"Fantini","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jgo.2026.104122_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8100090","article-title":"Photodynamic therapy for non-melanoma skin cancers","volume":"8","author":"Cohen","year":"2016","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.jgo.2026.104122_bb0305","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/cancers8100098","article-title":"Photodynamic therapy and non-melanoma skin Cancer","volume":"8","author":"Griffin","year":"2016","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jgo.2026.104122_bb0310","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13555-023-00888-1","article-title":"Advances in photodynamic therapy for the treatment of actinic keratosis and nonmelanoma skin Cancer: a narrative review","volume":"13","author":"Farberg","year":"2023","journal-title":"Dermatology and therapy"},{"issue":"12","key":"10.1016\/j.jgo.2026.104122_bb0315","first-page":"12","article-title":"Superficial radiation therapy for the treatment of nonmelanoma skin cancers","volume":"8","author":"McGregor","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"issue":"9","key":"10.1016\/j.jgo.2026.104122_bb0320","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1007\/s00432-023-04597-2","article-title":"Analysis of image-guided superficial radiation therapy (IGSRT) on the treatment of early-stage non-melanoma skin cancer (NMSC) in the outpatient dermatology setting","volume":"149","author":"Tran","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0325","first-page":"12","article-title":"Consensus guidelines on the use of superficial radiation therapy for treating nonmelanoma skin cancers and keloids","volume":"12","author":"Nestor","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jgo.2026.104122_bb0330","series-title":"StatPearls [Internet]","article-title":"Brachytherapy","author":"Mayer","year":"2025"},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0335","article-title":"High-dose-rate brachytherapy for the treatment of basal and squamous cell carcinomas on sensitive areas of the face: a report of clinical outcomes and acute and subacute toxicities","volume":"6","author":"Taylor","year":"2020","journal-title":"Adv Radiat Oncol"},{"issue":"20","key":"10.1016\/j.jgo.2026.104122_bb0340","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.3390\/cancers13205188","article-title":"Basal cell carcinoma treated with high dose rate (HDR) brachytherapy-early evaluation of clinical and Dermoscopic patterns during irradiation","volume":"13","author":"Krzysztofiak","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.jgo.2026.104122_bb0345","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.3390\/cancers14112649","article-title":"Transcriptional dynamics of DNA damage responsive genes in circulating leukocytes during radiotherapy","volume":"14","author":"Cruz-Garcia","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jgo.2026.104122_bb0350","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3857\/roj.2019.00381","article-title":"Effectiveness of radiotherapy for head and neck skin cancers: a single-institution study","volume":"37","author":"Kim","year":"2019","journal-title":"Radiat Oncol J"},{"issue":"3","key":"10.1016\/j.jgo.2026.104122_bb0355","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.radonc.2017.12.029","article-title":"Skin CanceR brachytherapy vs external beam radiation therapy (SCRiBE) meta-analysis","volume":"126","author":"Zaorsky","year":"2018","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2026.104122_bb0360","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13555-018-0277-7","article-title":"Hedgehog pathway inhibitors and their utility in basal cell carcinoma: a comprehensive review of current evidence","volume":"9","author":"Tay","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.jgo.2026.104122_bb0365","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4049\/jimmunol.1701044","article-title":"Inhibitors of the PD-1 pathway in tumor therapy","volume":"200","author":"LaFleur","year":"2018","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jgo.2026.104122_bb0370","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40257-023-00763-x","article-title":"Efficacy and safety of sonic hedgehog inhibitors in basal cell carcinomas: an updated systematic review and Meta-analysis (2009-2022)","volume":"24","author":"Nguyen","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jgo.2026.104122_bb0375","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40259-020-00428-9","article-title":"The role of anti-PD-1\/PD-L1 in the treatment of skin Cancer","volume":"34","author":"Patrinely","year":"2020","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.jgo.2026.104122_bb0380","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag021","article-title":"PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis","volume":"31","author":"Amir","year":"2026","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.jgo.2026.104122_bb0390","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005082","article-title":"Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma","volume":"10","author":"Ascierto","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826012762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826012762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:53:20Z","timestamp":1789206800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826012762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1879406826012762"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.104122","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-surgical therapies for localized non-melanoma skin cancer in older adults: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.104122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104122"}}